Bernal AJ, da Silva MMG, Musungaie DB, et al. - Researchers evaluated the efficacy and safety of treatment with molnupiravir initiated within 5 days after the onset of signs or symptoms in nonhospitalized, unvaccinated adults with mild-to-moderate, laboratory-confirmed coronavirus disease 2019 (Covid-19) and at least one risk factor for severe Covid-19 illness.

• A phase 3, double-blind, randomized, placebo-controlled trial was conducted. A total of 1,433 participants were randomly assigned to receive 800 mg of molnupiravir or placebo twice daily for 5 days.

• Outcomes revealed reduced risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19, in correlation with receiving early treatment with molnupiravir.